Structured Administration and Supply Arrangement (SASA)

|  |  |
| --- | --- |
| **TITLE:** | **Treatment of Syphilis Infection by Midwives** |

1. **Authority:**

Issued by the Chief Executive Officer of Health under Part 6 of the Medicines and Poisons Regulations 2016.

1. **Scope:**

This authorises Midwives working in a program providing antenatal healthcare to administer antibiotics, for the treatment of syphilis.

1. **Criteria:**

This SASA authorises the actions specified in the table below.

|  |  |
| --- | --- |
| Practitioner: | Midwives, with general registration, who have completed approved training in accordance with Appendix 1. |
| Practice setting: | Programs providing antenatal healthcare, which are operated or managed by WA Health or by a health service that is a member of the Aboriginal Health Council of Western Australia.All regions of WA. |
| Approved activity: | Administration – single dose |

|  |  |
| --- | --- |
| Approved medicines: | Benzathine benzylpenicillin 1.8 gram (2,400,000 units) intramuscular injection |
| Note:  | 900 mg benzathine benzylpenicillin = 1,200,000 units = 1016.6 mg benzathine benzylpenicillin tetrahydrate |

|  |  |
| --- | --- |
| Medical conditions: | Adults and mature minors (14 years and older), who are being treated by the program providing antenatal healthcare, with syphilis infection that is not known to have been previously treated:* cases confirmed by laboratory or point of care testing;
* empirical treatment of symptomatic cases; and
* sexual contacts of confirmed cases, only if they are also a patient of the antenatal program.[[1]](#footnote-1)
 |

1. **Conditions:**

The administration or supply of approved medicines under this SASA is subject to the conditions that:

* 1. Patient selection, administration, follow-up care and notification is in accordance with the *Guidelines for managing sexually transmitted infections and blood-borne viruses* (“The Silver Book”);
	2. Administration is not repeated for the same instance of the condition, without the direction of a medical practitioner, credentialed for a public health STI program by a Health Service Provider of the WA Health system, or contracted entity;
	3. The medicines are procured by an authorised person or an appropriate Medicines and Poisons Permit holder;
	4. Procurement and storage of the approved medicines is in accordance with Part 9 of the Medicines and Poisons Regulations 2016;
	5. Record keeping of administration is in accordance with Part 12 of the Medicines and Poisons Regulations 2016;
	6. Laboratory confirmed diagnosis of syphilis must be notified to the Director, Communicable Disease Control Directorate, Department of Health, by post, telephone or facsimile, preferably within 24 hours; and
	7. Notification must comply with the approved procedure for notification of communicable diseases and be in an approved format.
1. **References:**
	1. *Guidelines for managing sexually transmitted infections and blood-borne viruses.* Available at*:* <http://ww2.health.wa.gov.au/Silver-book>
	2. Communicable Disease Control Directorate. *Notification of Communicable Diseases.* Availableat: <http://ww2.health.wa.gov.au/Silver-book/STI-or-HIV-notification>
2. **Issued by:**

|  |  |
| --- | --- |
| **Name:** | Dr Andrew Robertson |
| **Position:** | Chief Health Officer |
| **Date:**  | 19 August 2021 |

|  |  |  |  |
| --- | --- | --- | --- |
| Enquiries to:  | Medicines and Poisons Regulation Branch | Number:  | 029/1-2021 |
|  | MPRB@health.wa.gov.au | Date:  | 19/08/2021 |

**APPENDIX 1**

|  |
| --- |
| **Approved Training** |

All Registered Midwives administering a medicine in accordance with this SASA must have successfully completed a course of training approved by the Chief Executive Officer of the Department of Health or an equivalent course provided by a Registered Training Organisation (RTO) or a university and must maintain their competency through updates every two years.

Approved courses must require participants to demonstrate satisfactory knowledge, understanding and minimum competencies in the following areas:

1. Sexual health history taking;
2. Sexual health and STI clinical assessment;
3. Pathology testing, including request and collecting samples;
4. Contraindications and adverse effects of benzathine benzylpenicillin;
5. STI health promotion and education;
6. STI contact tracing;
7. Communicable disease notification and referral; and
8. Reporting of suspected child sexual abuse.
1. All other asymptomatic sexual contacts of confirmed cases should be referred to a Public Health clinic or their General Practitioner. [↑](#footnote-ref-1)